Results of a phase 1, randomized, placebo-controlled first-in-human trial of griffithsin formulated in a carrageenan vaginal gel

HIV pre-exposure prophylaxis (PrEP) is dominated by clinical therapeutic antiretroviral (ARV) drugs. Griffithsin (GRFT) is a non-ARV lectin with potent anti-HIV activity. GRFT’s preclinical safety, lack of systemic absorption after vaginal administration in animal studies, and lack of cross-resistan...

Descripción completa

Detalles Bibliográficos
Autores principales: Teleshova, Natalia, Keller, Marla J., Fernández Romero, José A., Friedland, Barbara A., Creasy, George W., Plagianos, Marlena G., Ray, Laurie, Barnable, Patrick, Kizima, Larisa, Rodriguez, Aixa, Cornejal, Nadjet, Melo, Claudia, Cruz Rodriguez, Gearoff, Mukhopadhyay, Sampurna, Calenda, Giulia, Sinkar, Shweta U., Bonnaire, Thierry, Wesenberg, Asa, Zhang, Shimin, Kleinbeck, Kyle, Palmer, Kenneth, Alami, Mohcine, O’Keefe, Barry R., Gillevet, Patrick, Hur, Hong, Liang, Yupu, Santone, Gabriela, Fichorova, Raina N., Kalir, Tamara, Zydowsky, Thomas M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8775213/
https://www.ncbi.nlm.nih.gov/pubmed/35051209
http://dx.doi.org/10.1371/journal.pone.0261775

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8775213/
https://www.ncbi.nlm.nih.gov/pubmed/35051209
http://dx.doi.org/10.1371/journal.pone.0261775

Ejemplares similares